Immunome, Inc. · NASDAQ:IMNM

Immunome — Investor Presentation (January 2023)

27 slides from Immunome's investor presentation, Jan 30, 2023

  1. Slide 1: Harnessing the Power of the Human Memory B Cell

    Harnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com Copyright © 2023 Immunome, Inc. All rights reserved.

  2. Slide 2: Disclaimers and Forward-Looking Statements

    Disclaimers and Forward-Looking Statements This presentation includes certain disclosures that contain “forward-looking statements” All statements contained in this presentation are made as of the date specified on the cover, intended to qualify for the “safe harbor” from liability established by th

  3. Slide 3: Immunome: Three-Pronged Strategy

    Immunome: Three-Pronged Strategy Powered by Human Memory B Cell Interrogation 01 02 03 Successfully execute on AbbVie Extract value from the breadth of Advance proprietary oncology collaboration Immunome’s Discovery Engine pipeline → $30M upfront → Platform and asset-based → IMM-ONC-01 (targeting IL

  4. Slide 4: Strategic Discovery Collaboration with AbbVie

    Strategic Discovery Collaboration with AbbVie Immunome’s approach has the potential to unlock novel cancer biology and yield multiple therapeutic candidates. STEVE DAVIDSEN VP, Oncology Discovery Research, AbbVie Copyright © 2023 Immunome, Inc. All rights reserved. → AbbVie option to purchase worldw

  5. Slide 5: We See the Disease Through the Lens of a Memory B Cell

    We See the Disease Through the Lens of a Memory B Cell Interrogate Most Educated Components of Immune Response in an Unbiased Manner at Industrial Scale Patient responses unveil novel disease targets 01 02 03 Patients’ immune Proprietary Discovery Patient Ab responses responses recognize and Engine

  6. Slide 6: Broad Applicability Across Therapeutic Areas

    Broad Applicability Across Therapeutic Areas Unbiased Interrogation Unveils Targets & Underexplored Biology: Examples Oncology: Infectious Disease: Immunology: Target Rich Clusters Multi-modal Action Conserved Epitopes Targets identified across Unique insights into breadth Identification of antibodi

  7. Slide 7: Platform has Potential for Partnering Across Therapeutic Areas

    Platform has Potential for Partnering Across Therapeutic Areas 01 02 03 04 05 Oncology Neurology → Neuroinflammation Oncology, Hematology Immune Disorders → Various Malignancies → Immunology → Auto-Immune Disorders Anti-Infectives Solid Tumors IMM-BCP-01 (SARS-CoV-2 Antibody Cocktail) Copyright © 20

  8. Slide 8: Immunome Pipeline

    Immunome Pipeline Targets Identified from Authentic Human Immune Response POTENTIAL DISEASE PROGRAM OF RELEVANCE STAGE NEXT MILESTONE ONCOLOGY IMM-ONC-01 (Anti-IL-38) Squamous carcinomas of Preclinical IND submission Soluble Cytokine, Immune Modulator head & neck, Development mid-2023 Neutralize IL-

  9. Slide 9: Oncology Platform and Pipeline

    ONCOLOGY Platform and Pipeline Copyright © 2023 Immunome, Inc. All rights reserved.

  10. Slide 10: B cells: Critical Players in Immunity

    B cells: Critical Players in Immunity → B cell infiltration more closely associated with survival than T cell presence in multiple cancers Oncology → Success of I/O therapies appears to be associated with coordinated response including B cells and TLS in the unique context of each patient’s tumor mi

  11. Slide 11: Immunome's Discovery Engine

    Immunome’s Discovery Engine Functional B Cell Interrogation to Actionable Public Targets Memory B Cells Represent One of the Most Educated Components of the Human Immune System 01 02 03 B cells identify important Discovery Engine Functional screening targets within the natural interrogates patient p

  12. Slide 12: Unveiling Tumor Context

    Unveiling “Tumor Context” Novel Insights Into Tumor Targets and Biological Processes Antibody responses across diverse cancers Diverse Cancer Landscape highlight common areas of target-rich biology 14 >350 ~250K >70 CANCERS PATIENTS HYBRIDOMAS ANTIBODY / TARGET PAIR Immune Modulation Platform identi

  13. Slide 13: Ectopic Expression: A Unique Class of Targets

    Ectopic Expression: A Unique Class of Targets with Potentially High Tumor Selectivity High Throughput Identification of Antibody-Target Pairs for Novel Modalities Ectopic Expression High Throughput Functional Characterization: Example of a Typical Cascade 32 Antibodies Strong binding to tumor No bin

  14. Slide 14: Example of an Ectopically Expressed Target as an ADC

    Example of an Ectopically Expressed Target as an ADC 01 Ab Highly Selective for Selective Tumor Cell Single Protein Target 17. PR121-00372 Binding 40 Target B C11orf68 30 S-Score 20 10 0 0 00 00 00 00 10 20 30 40 Copyright © 2023 Immunome, Inc. All rights reserved. Raw Binding Signal Internalization

  15. Slide 15: ADC Market: New Targets and Technologies Likely to Accelerate Growth

    ADC Market: New Targets and Technologies Likely to Accelerate Growth 4 Significant Number Of Recent ADC Approvals 1 Recent Clinical Success and Approvals Fueling Significant Investment in the ADC Space Copyright © 2023 Immunome, Inc. All rights reserved. Clinical Landscape2,3 Robust Deal Activity in

  16. Slide 16: Novel Targets Could Drive Future ADC Market Growth

    Novel Targets Could Drive Future ADC Market Growth Commercial/Phase 3 Solid Tumor ADC Programs are Still Mostly Directed at a Limited Number of Known Targets1,2 FolR1 TF TROP2 TOMORROW Nectin4 HER2 Copyright © 2023 Immunome, Inc. All rights reserved. TODAY Differentiated IMNM Platform CECAM5 → High

  17. Slide 17: Substantial and Sustained Early-Stage ADC Partnering Activity

    Substantial and Sustained Early-Stage ADC Partnering Activity → New ADC platforms are improving clinical outcomes of ADC products, leading to several recent approvals → Large recent investments in ADC platforms expected to increase the demand for novel targets → Ectopically expressed targets represe

  18. Slide 18: Oncology Lead Program IMM-ONC-01

    Oncology Lead Program IMM-ONC-01 Copyright © 2023 Immunome, Inc. All rights reserved.

  19. Slide 19: Anti-IL-38 in Oncology

    Anti-IL-38 in Oncology Selective Immuno-oncology Therapy, IND Filing Anticipated Mid-2023 CPIs effective, but response rate is limited IgG1 IL-38 neutralizing antibody expected to: Cytokine-targeted therapies limited by inappropriate → Promote activated immunocyte TME context, off-target effects, po

  20. Slide 20: IL-38 is Expressed in Multiple Tumors

    20 Copyright © 2023 Immunome, Inc. All rights reserved. 3. 2. 1. log2TPM log2TPM 25% 23% Bladder Head & Neck Immunome Internal Data Source: Tempus Real-World Data Skin 53% 14% Esophagus (% of Patient Expression) 30% Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset 41% Prostate Lung, Squ

  21. Slide 21: IL-38 Expression is Associated with Reduced Immune Cell Infiltration

    IL-38 Expression is Associated with Reduced Immune Cell Infiltration IL-38 Overexpression Inhibits Infiltration High IL-38 Expression is Associated with Reduced of T cells into Tumors In Vivo Immune Cell Infiltration* → IL-38 high tumor samples correlate with reduced infiltration of multiple immune

  22. Slide 22: IMM-ONC-01 Anti IL-38 Antibody

    IMM-ONC-01 Anti IL-38 Antibody Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models1 Demonstration of Anti-Tumor Activity Induction of Anti-Tumor Memory (B16.F10 Model) (EMT6 Model) → Immunologically cold tumor model → ~40% response rate upon treatment with IMM-ONC-01 → IMM-ONC-01 sig

  23. Slide 23: IMM-ONC-01 Program Summary

    IMM-ONC-01 Program Summary IND Submission Anticipated in Mid-2023 → In vitro and in vivo preclinical research confirms antitumor activity of IMM-ONC-01 in solid tumors as a monotherapy → Gene expression profiling of patient tumors suggest normal IL-38 biology is co-opted by tumors of squamous origin

  24. Slide 24: Financial Overview and Intellectual Property Snapshot

    Financial Overview and Intellectual Property Snapshot → Cash at least through 3Q 2024 → Eligible for additional platform access and option payments during the research term in the AbbVie Collaboration → Platform enables flexible business model – partnerships and proprietary programs Platform technol

  25. Slide 25: Immunome At a Glance

    Immunome “At a Glance” Disruptive Platform Leveraging Human Immune Response → Enabled by patient memory B cell interrogation Discovery Of Novel → Widely applicable across therapeutic areas Antibody-Target Pairs → Platform uniquely suited to rapidly identify novel Antibody-Drug Conjugate (ADC) target

  26. Slide 26: Experienced Management Team

    Experienced Management Team Purnanand Sarma, PhD Former CEO of Taris Biomedical President & CEO Sold to Johnson & Johnson in 2019 Corleen Roche Former US CFO, Biogen Chief Financial Officer Former CFO, Global Vaccines, Wyeth/Pfizer Former CSO at Taris Biomedical Dennis Giesing, PhD Led BARDA funded

  27. Slide 27: Board of Directors

    Board of Directors Michael Rapp Managing Member, Chairman of the Board Broadband Capital Investments, LLC Former VP and CFO, Zynerba Pharmaceuticals, Inc. Richard Baron Former SVP and CFO, Globus Medical Former CFO, various biotech, managed care and generics companies John LaMattina, PhD Formerly Pr

Immunome — Investor Presentation (January 2023) on 6ix